Neonatal abstinence syndrome

Pediatrics

Volumn 134, Issue 2, 2014, Pages

  Kocherlakota, Prabhakar ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Benzodiazepines; Breastfeeding; Buprenorphine; Finnegan scores; Inhalants; Methadone; Methamphetamine; Morphine; Neonatal abstinence syndrome; Opioid abuse; Opioid receptors; Prescription opioids; Selective serotonin reuptake inhibitor; Withdrawal

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; CANNABIS; CHLORPROMAZINE; CLONIDINE; COCAINE; CODEINE; DIAMORPHINE; DIAZEPAM; ETHYL GLUCURONIDE; FATTY ACID ESTER; HYDROMORPHONE; ILLICIT DRUG; METHADONE; METHAMPHETAMINE; MORPHINE; NALOXONE; OPIATE; PAREGORIC; PHENCYCLIDINE; PHENOBARBITAL; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACUPUNCTURE; ALGORITHM; APNEA; BREAST FEEDING; CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG ABUSE; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; FINNEGAN SCORING SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERACTIVITY; HYPOTENSION; INFANT FEEDING; KANGAROO CARE; LOADING DRUG DOSE; MASSAGE; MECONIUM; MULTIPLE DRUG ABUSE; MUSIC THERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEWBORN; PACIFIER; PATHOPHYSIOLOGY; PATIENT MONITORING; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; ROOMING IN; SCORING SYSTEM; SOMNOLENCE; SYMPTOM; URINE; WATER BED; WITHDRAWAL SYNDROME;

BENZODIAZEPINES; BREASTFEEDING; BUPRENORPHINE; FINNEGAN SCORES; INHALANTS; METHADONE; METHAMPHETAMINE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIOID ABUSE; OPIOID RECEPTORS; PRESCRIPTION OPIOIDS; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; WITHDRAWAL;

ANIMALS; BREAST FEEDING; FEMALE; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; RISK FACTORS;

EID: 84905232988     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3524     Document Type: Review

References (187)

1. Heroin timeline. Heroin addiction. Available at: www.heroinaddiction.com/ heroin-timeline.html. Accessed October 12, 2013
2. Merry J. A social history of heroin addiction. Br J Addict Alcohol Other Drugs. 1975;70(3):307-310
3. Courtwright D. Dark Paradise: Opiate Addiction in America Before 1940. Cambridge, MA: Harvard University Press; 1982
4. Menninger-Lerchenthal E. Die morphin kranheit der neugeborenen morphine stischer mutter Monatsschr. F Kinderh. 1934;60:182-193
5. Happel TJ. Morphinism in its relation to the sexual functions and appetite and its effects on the offspring of the users of the drug. Tr M Soc Tennessee. 1892;162-179
6. Earle FB. Maternal opium habit and infant mortality. M Standard (Chicago). 1888;3:2
7. OD. Fetal morphine addiction, queries and minor notes. JAMA. 1903;40:1092
8. Perlstein MA. Congenital morphinism; a rare cause of convulsions in the newborn. J Am Med Assoc. 1947;135(10):633
9. Goodfriend MJ, Shey IA, Klein MD. The effects of maternal narcotic addiction on the newborn. Am J Obstet Gynecol. 1956;71(1):29-36
10. Cobrinik RW, Hood RT Jr, Chusid E. The effect of maternal narcotic addiction on the newborn infant; review of literature and report of 22 cases. Pediatrics. 1959;24(2):288-304
11. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936-1943
12. Reddy AM, Harper RG, Stern G. Observations on heroin and methadone withdrawal in the newborn. Pediatrics. 1971;48(3):353-358
13. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13(suppl 1):S17-S28
14. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) series 40. Rockville, MD: Substance Abuse and Mental Health Administration; 2004. DHHS publication (SMA) 04-3939
15. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachâtre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther. 1997;62(5):569-571 (Pubitemid 28214935)
16. Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction. 2003;98(11):1599-1604
17. Rao R, Desai NS. OxyContin and neonatal abstinence syndrome. J Perinatol. 2002;22(4):324-325 (Pubitemid 34619106)
18. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934-1940
19. O'Donnell M, Nassar N, Leonard H, et al. Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement. Pediatrics. 2009;123(4). Available at: www.pediatrics.org/cgi/content/full/123/4/e614
20. SAMHSA. Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2008-2011. Available at: www.samhsa.gov/data/ NSDUH/2011SummNatFindDetTables/NSDUH-DetTabsPDFWHTML2011/2k11DetailedTabs/Web/ HTML/NSDUH-DetTabsSect6peTabs55to107-2011.htm#Tab6.72A. Accessed February 25, 2013
21. Napolitano A, Theophilopoulos D, Seng SK, Calhoun DA. Pharmacologic management of neonatal abstinence syndrome in a community hospital. Clin Obstet Gynecol. 2013;56(1):193-201
22. Patrick SW, Benneyworth BD, Schumacher R, Davis MM. Variation in hospital type in treatment of neonatal abstinence syndrome in the United States. Paper presented at Pediatric Academic Societies Annual Meeting; May 4-7, 2013; Washington, DC. Abstract 2922
23. Tetstall E, Liu AJ, An EI, Canalese J, Nanan R. Pregnancy and neonatal characteristics of opioid-dependent Indigenous Australians: a rural and metropolitan comparison. Aust N Z J Obstet Gynaecol. 2009;49(3):279-284
24. Substance Abuse and Mental Health Administration. Report TEDS. Injection drug abuse admission to substance abuse treatment, 1999 to 2009. Available at: www.samhsa.gov/data/2k11/WEB-TEDS-012/WEB-TEDS-012.htm. Accessed February 25, 2013
25. Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE. Buprenorphine use: the international experience. Clin Infect Dis. 2006;43(suppl 4):S197-S215 (Pubitemid 44901888)
26. Shainker SA, Saia K, Lee-Parritz A. Opioid addiction in pregnancy. Obstet Gynecol Surv. 2012;67(12):817-825
27. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CJ, eds. Teratology and medications that affect the fetus. In: Williams Obstetrics. 23rd ed. New York, NY: McGraw Hill; 2010:328
28. Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol. 1999;26(1):173-183 (Pubitemid 29177807)
29. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25(1):139-151 (Pubitemid 28141705)
30. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985;233(1):1-6 (Pubitemid 15083518)
31. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999;18(4):51-61 (Pubitemid 30053427)
32. Seligman NS, Almario CV, Hayes EJ, Dysart KC, Berghella V, Baxter JK. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr. 2010;157(3):428-433, e1
33. Lim S, Prasad MR, Samuels P, Gardner DK, Cordero L. High-dose methadone in pregnant women and its effect on neonatal abstinence syndrome. Am J Obstet Gynecol. 2009;200:70.e1-70.e5
34. Pizarro D, Habli M, Grier M, Bombrys A, Sibai B, Livingston J. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat. 2011;40(3):295-298
35. Dashe J, Sheffield JS, Olscher DA, Todd SJ, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol. 2002;100:1244-1258
36. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol. 2005;193(3 pt 1):606-610 (Pubitemid 41261451)
37. Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction. 2010;105(12):2071-2084
38. Riksheim M, Gossop M, Clausen T. From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme. J Subst Abuse Treat. 2014;46:291-294
39. Soyka M. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs. 2013;27(8):653-662
40. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(suppl 1):5-27
41. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1):1-10 (Pubitemid 41557119)
42. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S; Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006;82(3):250-257
43. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101(2):275-281 (Pubitemid 43351601)
44. Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96(1-2):69-78
45. Bakstad B, Sarfi M, Welle-strand G, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15(3):128-134
46. Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67:1053-1059
47. Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127(1-3):200-206
48. Patel P, Abdel-Latif ME, Hazelton B, et al. Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants. J Paediatr Child Health. 2013;49(9):746-753
49. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331
50. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;(12):CD006318
51. Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend. 2014;134:414-417
52. Epstein RA, Bobo WV, Martin PR, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013;23(8):498-503
53. Buchi KF, Suarez C, Varner MW. The prevalence of prenatal opioid and other drug use in Utah. Am J Perinatol. 2013;30(3):241-244
54. Handal M, Engeland A, Rønning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study. Eur J Clin Pharmacol. 2011;67(9):953-960
55. Committee on Health Care for Underserved Women, The American College of Obstetricians and Gynecologists. Committee opinion no. 538: nonmedical use of prescription drugs. Obstet Gynecol. 2012;120(4):977-982
56. Kellogg A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol. 2011;204:259.e1-e4
57. Kelly L, Dooley J, Cromarty H, et al. Narcotic-exposed neonates in a First Nations population in northwestern Ontario: incidence and implications. Can Fam Physician. 2011;57(11):e441-e447
58. Winchester PD, Miller K, Proctor C, Singhal A, Ying J, Ellis G. Neonatal abstinence and opiate prescriptions. Paper presented at Pediatric Academic Societies Annual Meeting; April 28-May 1, 2012; Boston, MA. Abstract
59. Brown MS, Hayes MJ, LaBrie S. Breastfeeding is associated with decreased risk and length of treatment for neonatal abstinence syndrome in methadone and buprenorphine exposed infants. Paper presented at Pediatric Academic Societies; May 1-4, 2011; Vancouver, BC, Canada. Abstract
60. Kocherlakota P. Changing spectrum of neonatal abstinence syndrome. Paper presented at Pediatric Academic Societies; April 28-May 1, 2012; Boston, MA. Abstract
61. ACOG Committee on Practice Bulletins; Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001- 1020
62. Fenger-Gron J, Thomsen M, Andersen KS, Nielsen G. Pediatric outcomes following intrauterine exposure to serotonin reuptake inhibitors: a systemic review. Dan Med Bul. 2011;58:A4303
63. Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA. 2013;309(1):48-54
64. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257-1266
65. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Available at: www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/ NSDUHresults2012.pdf. Accessed January 14, 2014
66. United Nations Office on Drugs and Crime. Global smart update 2012. Volume 8. Available at: www.unodc.org/documents/scientific/Global-SMART-Update- 8-E-web.pdf. Accessed January 24, 2014
67. Oei JL, Kingsbury A, Dhawan A, et al. Amphetamines, the pregnant woman and her children: a review. J Perinatol. 2012;32(10):737-747
68. Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am. 1998;25(1):153-167 (Pubitemid 28141706)
69. Behnke M, Smith VC; Committee on Substance Abuse and Committee on Fetus and Newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131(3). Available at: www.pediatrics.org/cgi/ content/full/131/3/e1009
70. Tenenbein M, Casiro OG, Seshia MM, Debooy VD. Neonatal withdrawal from maternal volatile substance abuse. Arch Dis Child Fetal Neonatal Ed. 1996;74(3):F204-F207
71. Nanovskaya TN, Nekhayeva, Hankins GDV, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol. 2008:198:126.e1-e4
72. Szeto HH. Kinetics of drug transfer to the fetus. Clin Obstet Gynecol. 1993;36(2):246-254 (Pubitemid 23133160)
73. Malek A, Obrist C, Wenzinger S, von Mandach U. The impact of cocaine and heroin on the placental transfer of methadone. Reprod Biol Endocrinol. 2009;7:61
74. Scott CS, Riggs KW, Ling EW, et al. Morphine pharmacokinetics and pain assessment in premature newborns. J Pediatr. 1999;135(4):423-429
75. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current research on opioid receptor function. Curr Drug Targets. 2012;13(2):230-246
76. Barr GA, McPhie-Lalmansingh A, Perez J, Riley M. Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience. ILAR J. 2011;52:329-341
77. Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets. 2013;12(1):112-125
78. Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience. 2013;248:637-654
79. Little PJ, Price RR, Hinton RK, Kuhn CM. Role of noradrenergic hyperactivity in neonatal opiate abstinence. Drug Alcohol Depend. 1996;41(1):47-54 (Pubitemid 26185294)
80. Spiga S, Puddu MC, Pisano M, Diana M. Morphine withdrawal-induced morphological changes in the nucleus accumbens. Eur J Neurosci. 2005;22(9):2332-2340 (Pubitemid 41653546)
81. Radke AK, Rothwell PE, Gewirtz JC. An anatomical basis for opponent process mechanisms of opiate withdrawal. J Neurosci. 2011;31(20):7533-7539
82. Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195-206
83. Lauden J, Kerby LG. Opiate exposure and withdrawal dynamically regulate mRNA expression in the serotonergic dorsal raphe nucleus. Neuroscience. 2013;254:160-172
84. Capasso A, Gallo C. Molecules acting on CB1 receptor and their effects on morphine withdrawal in vitro. Open Biochem J. 2009;3:78-84
85. Nunez C, Földes A, Laorden ML, Milanes MV, Kovács KJ. Activation of stress-related hypothalamic neuropeptide gene expression during morphine withdrawal. J Neurochem. 2007;101(4):1060-1071 (Pubitemid 46683869)
86. Pasero C, McCaffery M. Opioid-induced hyperalgesia. J Perianesth Nurs. 2012;27(1):46-50
87. Juul SE, Beyer RP, Bammler TK, Farin FM, Gleason CA. Effects of neonatal stress and morphine on murine hippocampal gene expression. Pediatr Res. 2011;69(4):285-292
88. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118(6):933-937
89. Anand KJS, Anderson BJ, Holford NHG, et al NEOPAIN Trial Investigators Group. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680-689
90. Dysart K, Hsieh HC, Kaltenbach K, Greenspan JS. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med. 2007;35(4):344-346 (Pubitemid 47036964)
91. Sanj EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365(9458):482-487 (Pubitemid 40215730)
92. Chiu VM, Schenk JO. Mechanism of action of methamphetamine within the catecholamine and serotonin areas of the central nervous system. Curr Drug Abuse Rev. 2012;5(3):227-242
93. Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction. 2012;107(suppl 1):53-62
94. Herzlinger RA, Kandall SR, Vaughan HG Jr. Neonatal seizures associated with narcotic withdrawal. J Pediatr. 1977;91(4):638-641 (Pubitemid 8194457)
95. Jansson LM, Dipietro JA, Elko A, Velez M. Infant autonomic functioning and neonatal abstinence syndrome. Drug Alcohol Depend. 2010;109(1-3):198-204
96. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and NewbornAmerican Academy of Pediatrics Clinical Report. Neonatal drug withdrawal. Pediatrics. 2012;129(2). Available at: www.pediatrics.org/cgi/content/full/129/ 2/e540
97. Seligman NS, Salva N, Hayes EJ, Dysart KC, Pequignot EC, Baxter JK. Predicting length of treatment for neonatal abstinence syndrome in methadone exposed neonates. Am J Obstet Gynecol. 2008;199:396.e1-396.e7
98. Liu AJW, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust N Z J Obstet Gynaecol. 2010;50(3):253-258
99. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116(5):665-671
100. Sie SD, Wennink JM, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97(6):F472-F476
101. Chomchai C, Manaboriboon B. Stimulant methamphetamine and dextromethorphan use among Thai adolescents: implications for health of women and children. J Med Toxicol. 2012;8(3):291-294
102. Gaalema DE, Heil SH, Badger GJ, Metayer JS, Johnston AM. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. Drug Alcohol Depend. 2013;133(1):266-269
103. Oei J, Lui K. Management of the newborn infant affected by maternal opiates and other drugs of dependency. J Paediatr Child Health. 2007;43(1-2):9-18 (Pubitemid 44973395)
104. Cleary BJ, Eogan M, O'Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107(8):1482-1492
105. Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA. 2013;309(17):1821-1827
106. Jansson LM, Di Pietro JA, Elko A, Williams EL, Milio L, Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend. 2012;122(3):213-219
107. Johnson K, Greenough A, Gerada C. Maternal drug use and length of neonatal unit stay. Addiction. 2003;98(6):785-789 (Pubitemid 36688063)
108. Dabek MT, Porschl J, Englert S, Ruef P. Treatment of neonatal abstinence syndrome in preterm and term neonates. Klin Padiatr. 2013;225(5):252-256
109. Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction. 2012;107(suppl 1):45-52
110. Irner TB, Teasdale TW, Nielsen T, Vedal S, Olofsson M. Substance use during pregnancy and postnatal outcomes. J Addict Dis. 2012;31(1):19-28
111. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs. 2102;41: 180-190
112. O'Connor AB, O'Brien L, Alto WA. Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy? J Perinat Med. 2013;41(5):621-623
113. Unger A, Jagsch R, Bäwert A, et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? Gend Med. 2011;8(6):355-364
114. Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend. 2013;131(3):271-277
115. Wachman EM, Newby PK, Vreeland J, et al. The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med. 2011;5 (4):293-299
116. Cotten SW. Drug testing in the neonate. Clin Lab Med. 2012;32(3):449-466
117. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138(3):344-348 (Pubitemid 32207135)
118. Lozano J, García-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit. 2007;29(6):711-734 (Pubitemid 350190848)
119. Gourlay DL, Heit HA, Caplan YH. Urine drug testing in clinical practice: the art and science of patient care. 5th ed. Baltimore, MD: Johns Hopkins University School of Medicine; 2012
120. Cotten SW, Duncan DL, Burch EA, Seashore CJ, Hammett-Stabler CA. Unexpected interference of baby wash products with a cannabinoid (THC) immunoassay. Clin Biochem. 2012;45(9):605-609
121. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL. Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila). 2012;50(8):733-742
122. Kerrigan S, Mott A, Jatzlau B, et al. Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry. J Forensic Sci. 2014;59(1):175-183
123. Ingall GB. Alcohol biomarkers. Clin Lab Med. 2012;32(3):391-406
124. Murphy-Oikonen J, Montelpare WJ, Southon S, Bertoldo L, Persichino N. Identifying infants at risk for neonatal abstinence syndrome: a retrospective cohort comparison study of 3 screening approaches. J Perinat Neonatal Nurs. 2010;24(4):366-372
125. Hytinantti T, Kahila H, Renlund M, Järvenpää AL, Halmesmäki E, Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008;97(8):1040-1044
126. Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2(1-2):141-158
127. Mehta A, Forbes KD, Kuppala VS. Neonatal abstinence syndrome management from prenatal counseling to a post discharge follow-up care: results of a national survey. Hosp Pediatr. 2013;3(4):317-323
128. Maguire D, Cline GJ, Parnell L, Tai CY. Validation of the Finnegan Neonatal Abstinence Syndrome Tool-short form. Adv Neonatal Care. 2013;13(6):430-437
129. Zahorodny W, Rom C, Whitney W, et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. J Dev Behav Pediatr. 1998;19(2):89-93 (Pubitemid 128452748)
130. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol. 2006;26(1):15-17 (Pubitemid 43135249)
131. van Sleuwen BE, Engelberts AC, Boere-Boonekamp MM, Kuis W, Schulpen TW, L'Hoir MP. Swaddling: a systematic review. Pediatrics. 2007;120(4). Available at: www.pediatrics.org/cgi/content/full/120/4/e1097
132. Caiola E. Swaddling young infants can decrease crying time. J Pediatr. 2007;150(3):320-321 (Pubitemid 46328980)
133. D'Apolito K. Comparison of a rocking bed and standard bed for decreasing withdrawal symptoms in drug-exposed infants. MCN Am J Matern Child Nurs. 1999;24(3):138-144
134. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998;101(6):1079-1088
135. Filippelli AC, White LF, Spellman LW, et al. Non-insertive acupuncture and neonatal abstinence syndrome: a case series from an inner city safety net hospital. Glob Adv Health Med. 2012;1(4):48-52
136. Hunseler C, Bruckle M, Roth B, Kribs A. Neonatal opiate withdrawal and rooming in: a retrospective analysis of a single center experience. Klin Padiatr. 2013;225(5):247-251
137. Hodgson ZG, Abrahams RR. A rooming-in program to mitigate the need to treat for opiate withdrawal in the newborn. J Obstet Gynaecol Can. 2012;34(5):475-481
138. Kuschel C. Managing drug withdrawal in the newborn infant. Semin Fetal Neonatal Med. 2007;12(2):127-133 (Pubitemid 46366884)
139. Greig E, Ash A, Douiri A. Maternal and neonatal outcomes following methadone substitution during pregnancy. Arch Gynecol Obstet. 2012;286(4):843-851
140. Finnegan L, Kaltenach K. Neonatal abstinence syndrome. In: Hoekalman R, Friedman S, Nelson N, Sidel H, eds. Primary Pediatric Care. St Louis, MO: Mosby-Year Book; 1992:1367-1378
141. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. Pediatr Clin North Am. 2012;59(5):1147-1165
142. Sublett J. Neonatal abstinence syndrome: therapeutic interventions. MCN Am J Matern Child Nurs. 2013;38(2):102-107, quiz 107-109
143. Grim K, Harrison TE, Wilder RT. Management of neonatal abstinence syndrome from opioids. Clin Perinatol. 2013;40(3):509-524
144. Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2010;(10):CD002053
145. O'Grady MJ, Hopewell J, White MJ. Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed. 2009;94(4):F249-F252
146. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009;5(1):47-55
147. Backes CH, Backes CR, Gardner D, Nankervis CA, Giannone PJ, Cordero L. Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting. J Perinatol. 2012;32(6):425-430
148. Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. J Addict Med. 2013;7(2):113-115
149. Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed. 2004;89(4):F300-F304 (Pubitemid 38869667)
150. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol. 2011;31(11):692-701
151. Kapur BM, Hutson JR, Chibber T, Luk A, Selby P. Methadone: a review of drug-drug and pathophysiological interactions. Crit Rev Clin Lab Sci. 2011;48(4):171-195
152. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction. 2011;106(3):574-580
153. Leikin JB, Mackendrick WP, Maloney GE, et al. Use of clonidine in the prevention and management of neonatal abstinence syndrome. Clin Toxicol (Phila). 2009;47(6):551-555
154. Esmaeili A, Keinhorst AK, Scuster T, Beske F, Schosser R, Basanier C. Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. Acta Paediatr. 2010;99(2):209-214
155. Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123(5). Available at: www.pediatrics.org/cgi/content/full/123/ 5/e849
156. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789
157. Sachs HC. Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013;132(3): Available at www.pediatrics.org/cgi/content/full/132/3/e796
158. Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008;121(1):106-114
159. McCarthy JJ, Posey BL. Methadone levels in human milk. J Hum Lact. 2000;16(2):115-120
160. Ilett KF, Hackett LP, Gower S, Doherty DA, Hamilton D, Bartu AE. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med. 2012;7:269-274
161. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070-1076
162. Jansson LM; Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #21: Guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med. 2009;4(4):225-228
163. O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. J Midwifery Womens Health. 2013;58(4):383-388
164. Bogen DL, Perel JM, Helsel JC, Hanusa BH, Thompson M, Wisner KL. Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. Breastfeed Med. 2011;6(6):377-384
165. Lindemalm S, Nydert P, Svensson JO, Stahle L, Sarman I. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact. 2009;25(2):199-205
166. Isemann B, Meinzen-Derr J, Akinbi H. Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. J Perinatol. 2011;31(1):25-29
167. Sauberan JB, Anderson PO, Lane JR, et al. Breast milk hydrocodone and hydromorphone levels in mothers using hydrocodone for postpartum pain. Obstet Gynecol. 2011;117(3):611-617
168. Seaton S, Reeves M, McLean S. Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: relationships between maternal plasma, breast milk and neonatal plasma levels. Aust N Z J Obstet Gynaecol. 2007;47(3):181-185 (Pubitemid 46909295)
169. Madadi P, Avard D, Koren G. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab. 2012;13(6):721-727
170. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarkø L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr. 2013;102(11):1060-1066
171. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6). Available at: www.pediatrics.org/cgi/content/full/117/6/e1163
172. Wachman EM, Byrun J, Philip BL. Breast feeding rates among mothers of infants with neonatal abstinence syndrome. Paper presented at Pediatric Academic Society Meeting; May 1-4, 2012; Boston, MA
173. Conradt E, Sheinkopf SJ, Lester BM, et al. Prenatal substance exposure: neurobiological organization at 1 month. J Pediatr. 2013;163(4):989-994.ei
174. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev. 2008;84(1):29-35
175. Lester BM, Lagasse LL. Children of addicted women. J Addict Dis. 2010;29(2):259-276
176. Mei B, Niu L, Cao B, Huang D, Zhou Y. Prenatal morphine exposure alters the layer II/III pyramidal neurons morphology in lateral secondary visual cortex of juvenile rats. Synapse. 2009;63(12):1154-1161
177. Massa H, Lacoh CM, Vutskits L. Effects of morphine on the differentiation and survival of developing pyramidal neurons during the brain growth spurt. Toxicol Sci. 2012;130(1):168-179
178. Walhovd KB, Watts R, Amlien I, Woodward LJ. Neural tract development of infants born to methadone-maintained mothers. Pediatr Neurol. 2012;47(1):1-6
179. Walhovd KB, Moe V, Slinning K, et al. Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage. 2007;36(4):1331-1344 (Pubitemid 47001728)
180. Gentile S. Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depress Anxiety. 2010;27(7):675-686
181. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406-2415
182. Smith LM, LaGasse LL, Derauf C, et al. Motor and cognitive outcomes through three years of age in children exposed to prenatal methamphetamine. Neurotoxicol Teratol. 2011;33(1):176-184
183. Visconti K, Hennessy K, Towers C, Hannessy M, Howard B. Opiate abuse/usage in pregnancy and newborn head circumference. Am J Obstet Gynecol. 2013;208:S67-S68
184. Sundelin Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr. 2013;102(5):544-549
185. Gill AC, Oei J, Lewis NL, Younan N, Kennedy I, Lui K. Strabismus in infants of opiate-dependent mothers. Acta Paediatr. 2003;92(3):379-385 (Pubitemid 36408094)
186. Spiteri Cornish K, Hrabovsky M, Scott NW, Myerscough E, Reddy AR. The short- and long-term effects on the visual system of children following exposure to maternal substance misuse in pregnancy. Am J Ophthalmol. 2013;156(1):190-194
187. McGlone L, Hamilton R, McCulloch DL, et al. Neonatal visual evoked potentials in infants born to mothers prescribed methadone. Pediatrics. 2013;131(3). Available at: www.pediatrics.org/cgi/content/full/131/3/e857